|
JPH10130258A
(ja)
*
|
1996-10-10 |
1998-05-19 |
Eli Lilly & Co |
ベンゾ［ｂ］チオフェン化合物、中間体、製剤、および方法
|
|
US6271227B1
(en)
|
1997-04-30 |
2001-08-07 |
Eli Lilly And Company |
Antithrombotic Agents
|
|
WO1998048797A1
(en)
|
1997-04-30 |
1998-11-05 |
Eli Lilly And Company |
Antithrombotic agents
|
|
ATE286395T1
(de)
|
1997-04-30 |
2005-01-15 |
Lilly Co Eli |
Antithrombotische mittel
|
|
CA2288144A1
(en)
|
1997-04-30 |
1998-11-05 |
Eli Lilly And Company |
Antithrombotic agents
|
|
WO1998049161A1
(en)
|
1997-04-30 |
1998-11-05 |
Eli Lilly And Company |
Antithrombotic agents
|
|
US6541499B1
(en)
|
1997-05-01 |
2003-04-01 |
Eli Lilly And Company |
Antithrombotic agents
|
|
EP0988289A2
(en)
*
|
1997-06-05 |
2000-03-29 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compounds, their production and use
|
|
US6017914A
(en)
*
|
1997-09-03 |
2000-01-25 |
Eli Lilly And Company |
Benzo[b]thiophene compounds, intermediates, formulations, and methods
|
|
US6284756B1
(en)
|
1998-04-30 |
2001-09-04 |
Eli Lilly And Company |
Antithrombotic agents
|
|
US6166069A
(en)
*
|
1998-05-12 |
2000-12-26 |
American Home Products Corporation |
Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
|
|
DK0997460T3
(da)
*
|
1998-10-28 |
2003-03-31 |
Lilly Co Eli |
Benzothiophenforbindelser som antithrombotiske midler og mellemprodukter
|
|
ATE258934T1
(de)
|
1998-10-30 |
2004-02-15 |
Lilly Co Eli |
Azaindol derivate und ihre verwendung als antithrombotische wirkstoffe
|
|
ATE259802T1
(de)
*
|
1999-11-19 |
2004-03-15 |
Lilly Co Eli |
Verbindungen mit antithrombotischer wirkung
|
|
CA2444787A1
(en)
|
2001-05-22 |
2002-11-28 |
Eli Lilly And Company |
Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
|
|
DE60210283T2
(de)
|
2001-05-22 |
2006-11-09 |
Eli Lilly And Co., Indianapolis |
2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
|
|
JP5082033B2
(ja)
|
2001-12-21 |
2012-11-28 |
エグゼリクシス パテント カンパニー エルエルシー |
Ｌｘｒのモジュレーター
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
HRP20041233A2
(en)
*
|
2002-07-22 |
2005-02-28 |
Eli Lilly And Company |
Selective estrogen receptor modulators containing a phenylsulfonyl group
|
|
WO2005011751A2
(en)
*
|
2003-07-31 |
2005-02-10 |
University Of Pittsburgh |
Measuring device and method of measuring
|
|
US8785403B2
(en)
|
2003-08-01 |
2014-07-22 |
Mitsubishi Tanabe Pharma Corporation |
Glucopyranoside compound
|
|
TWI385177B
(zh)
|
2003-08-01 |
2013-02-11 |
Mitsubishi Tanabe Pharma Corp |
吡喃葡萄糖基衍生物及其製造方法
|
|
US8278290B2
(en)
|
2005-02-14 |
2012-10-02 |
Biononics Limited |
Tubulin polymerisation inhibitors
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
UY30730A1
(es)
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
|
CA2699285C
(en)
|
2007-09-10 |
2016-12-13 |
Ahmed F. Abdel-Magid |
Process for the preparation of compounds useful as inhibitors of sodium-dependent glucose transporter (sglt)
|
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
|
KR101730920B1
(ko)
|
2009-10-14 |
2017-04-27 |
얀센 파마슈티카 엔.브이. |
Ｓｇｌｔ2의 억제제로서 유용한 화합물의 제조 방법
|
|
HRP20161231T1
(hr)
|
2010-05-11 |
2016-11-04 |
Janssen Pharmaceutica N.V. |
Farmaceutske formulacije koje sadrže derivate 1-(beta-d-glukopiranozil)-2-tienilmetilbenzena kao sglt inhibitore
|
|
US10544135B2
(en)
|
2011-04-13 |
2020-01-28 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of SGLT2
|
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
|
|
JP6047582B2
(ja)
|
2011-12-15 |
2016-12-21 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ |
置換ベンゾチエニル−ピロロトリアジンおよび癌の処置におけるその使用
|
|
WO2013124316A1
(en)
|
2012-02-23 |
2013-08-29 |
Bayer Intellectual Property Gmbh |
Substituted benzothienyl-pyrrolotriazines and uses thereof
|
|
KR20170118687A
(ko)
*
|
2015-02-19 |
2017-10-25 |
제이엔씨 주식회사 |
벤조티오펜을 가지는 액정성 화합물, 액정 조성물 및 액정 표시 소자
|
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
|
CA3026784A1
(en)
|
2016-06-07 |
2017-12-14 |
Jacobio Pharmaceuticals Co., Ltd. |
Heterocyclic pyrazine derivatives useful as shp2 inhibitors
|
|
MY200227A
(en)
|
2017-03-23 |
2023-12-15 |
Jacobio Pharmaceuticals Co Ltd |
Novel heterocyclic derivatives useful as shp2 inhibitors
|
|
US20210393623A1
(en)
|
2018-09-26 |
2021-12-23 |
Jacobio Pharmaceuticals Co., Ltd. |
Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
|